Company intelligence / Profile preview

NTZ Lab

Ownership: Private
Development stage: Preclinical

Overview

NTZ Lab is an early-stage biotech focused on the discovery and development of small molecules and radioligands for central nervous system disorders. All known pipeline programs are currently at the preclinical stage, with no clinical results reported yet

Therapeutic areas: Neurology
Modalities: Small moleculeRadioligandDrug-like molecule (general)
Industry: Biotech

Drug pipeline

5 assets

NTZ-1010

Preclinical

4 more assets in the full pipeline.

Partnerships

Works closely with major universities and scientific institutions such as Bulgarian Academy of Sciences (BAS); seeking external research collaborations

Beyond the preview

Go deeper on NTZ Lab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTZ Lab.